Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office (Q45330154)

From Wikidata

Jump to navigation Jump to search

scientific article published in May 2012

Language	Label	Description	Also known as
English	Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office	scientific article published in May 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

0 references

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Helen S Yee

1

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Michael F Chang

2

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Christine Pocha

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Joseph Lim

4

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

David Ross

5

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Timothy R Morgan

6

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Alexander Monto

7

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Department of Veterans Affairs Hepatitis C Resource Center Program

8

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

National Hepatitis C Program Office

9

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

language of work or name

0 references

publication date

1 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

107

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

669-89; quiz 690

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Elevated prevalence of hepatitis C infection in users of United States veterans medical centers

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Progression of fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

New and experimental therapies for HCV.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Risks of a range of alcohol intake on hepatitis C-related fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Noninvasive measures of liver fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Performance of transient elastography for the staging of liver fibrosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Management of chronic hepatitis C in veterans: the potential of integrated care models

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Telaprevir for previously treated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2012.48

21 January 2018

Identifiers

10.1038/AJG.2012.48

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45330154&oldid=2074687665"